Business Context and Reporting Period
Company: Insight Molecular Diagnostics Inc. (IMDX), formerly Oncocyte Corporation.
Filing Type: Form 10-K Annual Report.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: iMDx is a diagnostics technology company focused on molecular testing for organ transplant rejection (GraftAssure family) and oncology. The company operates a CLIA-certified laboratory in Franklin, Tennessee, and R&D labs in Nashville, Tennessee, and Göttingen, Germany. In June 2025, the company rebranded and relocated its headquarters from Irvine, California, to Nashville, Tennessee.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Net Revenue | $4,055 | $1,881 |
| Gross Profit | $2,298 | $740 |
| Net Loss | $(50,222) | $(60,663) |
| Operating Cash Flow | $(22,184) | $(20,689) |
| Cash and Cash Equivalents (Year End) | $11,583 | $8,636 |
| Accumulated Deficit | $(400,761) | $(350,539) |
| Contingent Consideration Liability | $43,883 | $37,939 |
Note: Revenue is primarily derived from Laboratory Services ($4.03M in 2025). Kitted Products revenue was $24,000 in 2025, representing the first commercial sales of GraftAssureIQ.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 116% to $4.1 million, driven by a 117% increase in Laboratory Services revenue. The company recorded its first Kitted Products revenue of $24,000.
- Net Loss Reduction: Net loss decreased by $10.4 million (17%) to $50.2 million. This improvement was primarily due to a $27.3 million decrease in impairment losses and higher revenue, partially offset by a $10.2 million swing in the fair value of contingent consideration (from a gain in 2024 to a loss in 2025).
- Impairment Charges: The company recorded $14.6 million in impairment losses in 2025 related to the full impairment of oncology intangible assets (DetermaIO and DetermaCNI), compared to $41.9 million in 2024.
- Operating Expenses: Research and Development (R&D) expenses increased 62% to $15.9 million due to clinical trial costs for GraftAssureDx. Sales and Marketing expenses increased 61% to $6.3 million to support commercialization efforts.
Guidance, Outlook, and Risks
Outlook and Strategy:
- The company is shifting strategic focus from oncology to organ transplant diagnostics, specifically the GraftAssure family (Core, IQ, and Dx).
- In March 2026, iMDx submitted a data package to the FDA seeking marketing authorization for GraftAssureDx (IVD kit).
- Management believes current cash and recent capital raises are sufficient to fund operations for at least the next 12 months.
Recent Capital Raises (Subsequent Events):
- February 2025 Offering: Raised approximately $28.7 million net.
- February 2026 Offering: Raised approximately $24.6 million net to fund R&D in the transplantation category.
Key Risks and Contingencies:
- Reimbursement Dependency: Commercial success depends heavily on Medicare (CMS) and private payer reimbursement. A draft Local Coverage Determination (LCD) in July 2025 proposed capping the number of surveillance tests per year, which could materially impact revenue.
- Regulatory Uncertainty: While LDTs currently benefit from FDA enforcement discretion, future regulatory changes could require costly pre-market approvals.
- Liquidity: The company has incurred operating losses since inception and relies on equity financing. Continued losses are expected until commercialization scales.
- Contingent Consideration: Significant liabilities ($43.9M) exist related to acquisitions of IGI and Chronix, subject to milestone achievements and revenue royalties.
Investor Verification Checklist
- Reimbursement Status: Verify the final status of the MolDx draft LCD (L38671) regarding test caps for kidney, heart, and lung surveillance.
- FDA Submission: Confirm the timeline for FDA review of the GraftAssureDx data package submitted in March 2026.
- Capital Runway: Assess the burn rate relative to the $24.6M raised in February 2026 and the $11.6M cash on hand as of year-end 2025.
- Contingent Liabilities: Review the assumptions used to value the $43.9M contingent consideration liability, particularly regarding the probability of achieving IGI and Chronix milestones.
- Bio-Rad Partnership: Evaluate the terms of the strategic collaboration with Bio-Rad, including royalty obligations and the potential for Bio-Rad to exercise exclusive marketing rights for IVD kits.